GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Inventory-to-Revenue
Switch to:

Biohaven (NYSE:BHVN) Inventory-to-Revenue

: 0.00 (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biohaven's Average Total Inventories for the quarter that ended in Sep. 2022 was $0.00 Mil. Biohaven's Revenue for the three months ended in Sep. 2022 was $0.00 Mil.

Biohaven's Inventory-to-Revenue for the quarter that ended in Sep. 2022 stayed the same from Jun. 2022 (0.00) to Jun. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Biohaven (NYSE:BHVN) Inventory-to-Revenue Historical Data

The historical data trend for Biohaven's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Inventory-to-Revenue - -

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Inventory-to-Revenue Premium Member Only - - - - -

Biohaven (NYSE:BHVN) Inventory-to-Revenue Competitive Comparison

For the Biotechnology subindustry, Biohaven's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven (NYSE:BHVN) Inventory-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biohaven's Inventory-to-Revenue falls into.



Biohaven Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biohaven's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Inventory-to-Revenue (A: Dec. 2021 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2020 ) + Total Inventories (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

Biohaven's Inventory-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue (Q: Sep. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Jun. 2022 ) + Total Inventories (Q: Sep. 2022 )) / count ) / Revenue (Q: Sep. 2022 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven  (NYSE:BHVN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biohaven's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2022 )/Cost of Goods Sold (Q: Sep. 2022 )*Days in Period
=0/0*365 / 4
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biohaven's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2022 ) / Average Total Inventories (Q: Sep. 2022 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biohaven's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Executives
Robert J Hugin director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership